share_log

Reported Earlier, Takeda Announces U.S. FDA Approval Of ENTYVIO Subcutaneous Administration For Maintenance Therapy In Moderately To Severely Active Crohn's Disease

Moomoo 24/7 ·  Apr 19 02:27

ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment